Bayer AG NA

TickerBAYN.XETRA
Current Price –
Bayer AG NA – stock chart

5-year stock timeline

2026-02-17 — Proposed U.S. nationwide Roundup class settlement; litigation provisions increased

Monsanto (Bayer) announced a proposed nationwide class settlement to resolve current and future Roundup™ (glyphosate) claims through a long-term claims program. Monsanto will make declining capped annual payments for up to 21 years totaling up to $7.25 billion. Bayer said the resolutions and related costs would increase its provisions and litigation liabilities and shifted its 2025 results announcement to reflect the settlement accounting [9].

Market and investor reaction framed this as an effort to put long-running glyphosate litigation largely behind the company and to replace episodic large jury verdicts with a predictable long-dated payment stream. The move was presented as de-risking the balance sheet and enabling management to refocus on operations and capital allocation, though investors noted near-term cash flow and funding pressures from the payouts and bond maturities.

Bayer stated that provisions and liabilities for litigation would rise from €7.8 billion (including €6.5 billion for glyphosate) as of 30 September 2025 to €11.8 billion (including €9.6 billion for glyphosate). Estimated litigation-related payouts in 2026 could be about €5.0 billion. The company also disclosed an $8 billion bank loan facility to secure immediate financing and said ultimate financing would use senior bonds and equity-credit instruments [9].

2025 — Continued litigation outcomes, balance-sheet focus and guidance timing

During 2025 Bayer continued to resolve individual Roundup and PCB cases while preparing its year-end financials and updated guidance. Litigation provision builds and settlements remained a central corporate issue driving disclosure and timing of results [9].

Investors saw 2025 as the year when litigation cashflows and provisions dominated capital allocation and near-term free cash flow, but also as the period when management aimed to close legacy litigation risk so the market could re-rate Bayer on operating performance in Pharma, Crop Science and Consumer Health.

Bayer reported litigation provisions (carryover from 30 September 2025 figures) in the €7.8 billion range prior to the 2026 settlement announcement, of which €6.5 billion related to glyphosate [9].

2024 — Supervisory Board and governance steps; preparatory board-level changes after investor pressure

Bayer's Supervisory Board and governance disclosures reflected the completed CEO succession planning and emphasized strategic review outcomes presented at the 2024 Annual Stockholders' Meeting and related supervisory board communications [4][11].

After years of investor pressure over strategy and returns following the Monsanto acquisition, governance messaging in 2024 emphasized leadership renewal, strategic review and an intent to improve capital discipline and operational execution. This shifted investor perception from litigation-dominated headline risk toward a turnaround and reshaping narrative under new leadership.

Public filings and supervisory-board material documented the appointment timetable (Bill Anderson appointed to Board of Management effective 1 April 2023; CEO since 1 June 2023) and referenced the 2023 sales level of approximately €50.7 billion (currency- and portfolio-adjusted sales increase approximately 9%) as background for strategic evaluation [4][15].

2023 — CEO change: Bill Anderson named CEO; Werner Baumann retirement

Bayer announced an external CEO hire. Bill Anderson (ex-Roche Pharmaceuticals executive) was appointed to the Board of Management effective 1 April 2023 and became CEO on 1 June 2023. Werner Baumann, who led the Monsanto acquisition, retired at end of May 2023 [6][11].

The appointment of an outsider with a strong pharma background signaled to markets a break with the prior era and investor impatience with returns. Investors interpreted the move as a potential catalyst for operational refocus, possible portfolio moves, and governance reform to restore credibility after years of litigation and underperformance — shifting perception toward a possible turnaround if execution and litigation resolution progressed.

Bayer reported currency- and portfolio-adjusted sales of about €50.7 billion for the prior reporting period and governance disclosures documented the succession timeline [15][11].

2021 — Legacy litigation and Monsanto acquisition aftermath; earnings and reputation impact

Bayer spent 2021 continuing to address the fallout from Monsanto's Roundup litigation (large numbers of plaintiff cases, jury verdicts, and settlement negotiations) and managing the financial and reputational consequences of the Monsanto acquisition completed in 2018.

Through 2021 investors viewed Bayer as still heavily affected by legacy litigation risk and headline legal outcomes, which impaired the company's growth narrative and contributed to a perception of constrained upside and a value/turnaround trade rather than a safe compounder. Pressure mounted for governance change and clearer plans to resolve liabilities.

Public reporting in the period documented substantial litigation exposures and settlement negotiations (leading to later large settlement programs), and the company's multi-billion euro provisions and settlement discussions in subsequent years traceable to the litigation originating before and during 2021 [5][9].

Key risks and downside factors

Bayer AG operates across three distinct life-sciences businesses: Pharmaceuticals, Consumer Health, and Crop Science, each with its own competitive landscape. In Crop Science, the company confronts sustained pressure from large global agricultural-chemicals and seeds manufacturers alongside regional generic producers, with pricing intensity across the sector. Its Pharmaceutical division competes against global innovators primarily on research capability, patent strength, and execution in bringing drugs to market. The business faces material headwinds from product litigation and legal claims, expiring patents and regulatory approvals that compress margins and revenue, and exposure to commodity prices, geopolitical shifts, and supply-chain disruptions that influence both production costs and farmer purchasing behavior.

  • Large-scale litigation and settlement exposures tied to glyphosate and Roundup products, along with other product-related lawsuits, create material risks for substantial cash outflows and contingent liabilities.
  • Patent expirations and loss of exclusivity in major pharmaceutical products create exposure to generic competition, often resulting in sharp revenue declines for affected therapies.
  • Price competition has intensified as generic and commodity crop protection products gain market share, putting sustained pressure on Crop Science margins.
  • Geopolitical tensions, supply-chain disruptions, and swings in input costs—particularly energy and agrochemical intermediates—tend to raise production expenses and dampen farmer purchasing decisions.

Competitive landscape

Bayer AG operates across three major divisions—Crop Science, Pharmaceuticals, and Consumer Health—positioning it within a competitive landscape that includes large agrochemical and seed companies, diversified chemical firms with agricultural operations, and major pharmaceutical players. Near-term pressures stem from ongoing glyphosate litigation tied to Roundup™, which creates uncertainty around cash flow and financial provisions. The company also faces headwinds from regulatory shifts affecting crop protection products and genetically modified traits, alongside competitive erosion from specialized players in agriculture and pharmaceuticals that can compress margins and market position.

Private competitors

  • Global seed/trait specialists and ag‑tech startups (examples: private digital ag and biologicals developers)

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial

Performance Figures of Bayer AG NA

in EUR

1M High / Low
57.84 / 43.08
52W High / Low
57.84 / 26.64
5Y High / Low
67.99 / 18.38
1M
+28.66%
3M
+16.44%
6M
+45.26%
1Y
+107.63%
3Y
+66.44%
5Y
+26.76%

Relative Performance vs Benchmarks

PeriodBayer AG NA vs DAX vs S&P 500 (SPY)
1M +28.66% +26.95% +33.71%
3M +16.44% +17.97% +20.84%
6M +45.26% +41.85% +46.83%
1Y +107.63% +96.52% +96.24%
3Y +66.44% +4.59% -0.24%
5Y +26.76% -32.50% -39.75%

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial

Historical valuation trends

How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.

PeriodP/E RatioP/S RatioP/B RatioP/CF Ratio
Current-38.01.21.917.7
1Y ago-135.80.60.94.0
3Y ago-11.10.91.215.8
5Y ago329.51.11.617.3

Frequently Asked Questions

Where is the Bayer AG NA stock traded?

The Bayer AG NA stock trades under the ticker BAYN.XETRA on the XETRA exchange. ISIN: DE000BAY0017.

What does Bayer AG NA do?

Bayer AG NA is a company characterized by the following investment thesis:

What are the key metrics for BAYN.XETRA?

Key metrics for BAYN.XETRA include valuation (P/E 0, P/S 1.2, P/B 1.9), profitability (profit margin -3.16%, ROE -4.93%), and growth (revenue –, earnings –). Market capitalization is 55.15B EUR. These metrics give an overview of the company's financial performance and valuation.

How has Bayer AG NA's stock price performed?

Bayer AG NA's stock has returned – over 1 year, – over 3 years, and – over 5 years. Performance can vary depending on market conditions and company developments.

How is BAYN.XETRA valued?

BAYN.XETRA has the following valuation metrics: P/E Ratio: 0, P/S Ratio: 1.2, P/B Ratio: 1.9. These metrics help assess whether the stock is fairly valued compared to its fundamentals.

Does BAYN.XETRA pay dividends?

Yes, BAYN.XETRA pays dividends with a dividend yield of 0.2%. Dividends can be an important component of the total return on an investment.

What are the key risks when investing in BAYN.XETRA?

Key risks for BAYN.XETRA include: Bayer AG operates across three distinct life-sciences businesses: Pharmaceuticals, Consumer Health, and Crop Science, each with its own competitive landscape. In Crop Science, the company confronts sustained pressure from large global agricultural-chemicals and seeds manufacturers alongside regional generic producers, with pricing intensity across the sector. Its Pharmaceutical division competes against global innovators primarily on research capability, patent strength, and execution in bringing drugs to market. The business faces material headwinds from product litigation and legal claims, expiring patents and regulatory approvals that compress margins and revenue, and exposure to commodity prices, geopolitical shifts, and supply-chain disruptions that influence both production costs and farmer purchasing behavior.
  • Large-scale litigation and settlement exposures tied to glyphosate and Roundup products, along with other product-related lawsuits, create material risks for substantial cash outflows and contingent liabilities.
  • Patent expirations and loss of exclusivity in major pharmaceutical products create exposure to generic competition, often resulting in sharp revenue declines for affected therapies.
  • Price competition has intensified as generic and commodity crop protection products gain market share, putting sustained pressure on Crop Science margins.
  • Geopolitical tensions, supply-chain disruptions, and swings in input costs—particularly energy and agrochemical intermediates—tend to raise production expenses and dampen farmer purchasing decisions.
Investors should consider these risk factors carefully before making an investment decision.

Who are the main competitors of Bayer AG NA?

Bayer AG NA competes with several listed peers in its sector. Bayer AG operates across three major divisions—Crop Science, Pharmaceuticals, and Consumer Health—positioning it within a competitive landscape that includes large agrochemical and seed companies, diversified chemical firms with agricultural operations, and major pharmaceutical players. Near-term pressures stem from ongoing glyphosate litigation tied to Roundup™, which creates uncertainty around cash flow and financial provisions. The company also faces headwinds from regulatory shifts affecting crop protection products and genetically modified traits, alongside competitive erosion from specialized players in agriculture and pharmaceuticals that can compress margins and market position.
  • Corteva, Inc. (CTVA.NYSE)
  • Syngenta Group Co. Ltd. (public via Sinochem/Syngenta listings) (SYNN.SIX)
  • BASF SE (BAS.XETRA)
  • FMC Corporation (FMC.NYSE)
  • UPL Limited (UPL.NSE)
  • Pfizer Inc. (PFE.NYSE)
  • Merck & Co., Inc. (MRK.NYSE)
These competitors influence pricing power, growth opportunities and relative valuation.

When does Bayer AG NA report earnings?

Bayer AG NA's next earnings report date is February 24, 2027.

Key Metrics

Market Capitalization
55.15B EUR
P/E Ratio
0.00
Analyst Target Price
–

Valuation Metrics

P/S Ratio
1.21
P/B Ratio
1.92

Profitability Metrics

Profit Margin
-3.16%
Operating Margin
3.71%
Return on Equity
-4.93%
Return on Assets
-1.33%

Growth Metrics

Revenue Growth
–
Earnings Growth
–

Dividend history

Long-term record of paid dividends (amount per share and dividend yield at the time of payment).

YearDividendYield at paymentAvg. yield
20260.11 EUR0.29%2.51%
20250.11 EUR0.48%
20240.11 EUR0.40%
20232.40 EUR4.02%
20222.00 EUR3.18%
20212.00 EUR3.68%
20202.80 EUR4.44%
20192.80 EUR4.55%
20182.76 EUR2.73%
20172.66 EUR2.38%
20162.46 EUR2.48%
20152.21 EUR1.64%
20142.07 EUR2.07%
20131.87 EUR2.34%
20121.62 EUR2.96%

Earnings history & estimates

Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.

Historical earnings performance

65.6%
Beat estimate
28.1%
Miss estimate
+13.44%
Avg surprise when beat
-9.42%
Avg surprise when miss

Reports analyzed: 64

Upcoming earnings report

February 24, 2027
Next earnings date

Analyst estimates for upcoming periods

Next year
December 31, 2027
Consensus4.83
Range4.29 – 5.34
16 analysts
Est. growth vs prior: 5.91%
Revisions: 7d ↑7 ↓0 · 30d ↑8 ↓5
Next quarter
March 31, 2027
Consensus2.73
Range2.73 – 2.73
1 analysts
Est. growth vs prior: 0.74%
Revisions: 7d ↑1 ↓0 · 30d ↑1 ↓0

Key financial figures

All figures in EUR

Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.

20252024202320222021
Revenue45.58B46.61B47.64B50.74B44.08B
Operating income (EBIT)6.95B4.48B8.41B8.24B7.93B
Net income-3.62B-2.55B-2.94B4.15B1.00B
Free cash flow2.08B4.59B2.37B4.14B2.48B
Total assets110.61B110.85B116.26B124.88B120.24B
Equity25.95B31.91B32.93B38.77B33.02B
Net debt30.77B34.55B38.88B36.48B34.97B
© Leeway
PWP Leeway UG (haftungsbeschränkt)
Leeway Icon